Evidence Strategy (HEOR) Archives

Blog

How AI and Patient-Level Data Help Oncology Teams Define New Markets

September 8, 2026

Oncology markets are no longer defined only by tumor type or line of therapy. AI, patient-level data, and primary research now help teams define markets by biology, care pathways, and access barriers. That shift can shape development strategy, trial design, and...

Market Access Trends 2026

How Four Pillars Are Shaping Latin America and MENA Market Access

March 25, 2026

Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models, and...

Market Access Trends 2026

How Regulatory–HTA Convergence Is Reshaping European Market Access

March 24, 2026

Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring the...

Market Access Trends 2026

How MFN and Direct-to-Consumer Models Are Rewiring US Market Access

March 23, 2026

Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access 2026:...

Blog

Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments

January 17, 2025

One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments...

Blog

Key Takeaways and Learnings from ISPOR Europe 2023

December 7, 2023

Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both...

Blog

The Future of AI for Market Access: An ISPOR US 2023 Recap

July 17, 2023

This year Trinity team members at ISPOR 2023 attended several symposia and presentations on the use of Artificial Intelligence (AI) to support biopharma evidence generation. Among many industry trends, experts anticipate that AI and machine learning will increasingly be leveraged to...

Worktable with computer, digital brain and globe superimposed

Blog

ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?

June 21, 2023

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...